AHPA on NDIs
This article was originally published in The Tan Sheet
Executive Summary
"A single NDI notification may be submitted for more than one dietary supplement that contains the NDI that is the subject of the notification," AHPA maintains in a Feb. 24 addendum to previously submitted comments. "Dietary supplements that contain up to 100 mg per serving of the NDI; that are in the form of a capsule or tablet; and that are recommended to be used by adults over the age of 18 in a manner that limits daily consumption of the NDI to not more than 1,000 mg per day for up to 6 months" is a statement that would reduce the need for redundant filings, the trade group suggests. In this vein, manufacturers, marketers and distributors who sell supplements that conform to the dose and use parameters outlined in the notifications should not have to file their own NDI submissions...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.